Taking into consideration the positive results of harmaline treatment, we suppose that the use of this MAO-A-inhibitor agent might provide a potential therapeutic strategy in the prevention and treatment of I/R-related eye disorders. The gene discussed is MAOA; the disease is eye disorder.